Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
AC Immune SA
AC Immune SA
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
AC Immune strengthens management, appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover
Pharmaceutical
AC Immune SA appoints Dr Marie Kosco-Vilbois
Neurodegenerative Disease company has new Chief Scientific Officer
Pharmaceutical
New strategic partnership focuses on Alzheimers
Swiss AC Immune and Chinese WuXi Biologics sign agreement
Research & Development
AC Immune and Lilly announce licence and collaboration agreement
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases
Pharmaceutical
Landmark for AC Immune Alzheimer and Down Syndrome vaccines
The swiss clinical stage biopharmaceutical company has a broad pipeline focused on neurodegenerative diseases
Subscribe now